Marilyn Bui, MD, PhD

Articles

Future Perspectives on the Treatment of Desmoid Tumors

February 19th 2024

A panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.

Nirogacestat's Impact on the Future Treatment of Desmoid Tumors

February 19th 2024

Expert oncologists discuss the recent approval of nirogacestat for the treatment of desmoid tumors and explore its impact on clinical practice and the future treatment landscape.

Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors

February 12th 2024

A panel of oncology experts discuss the impact of nirogacestat on pain symptoms and quality of life indicators for individuals with desmoid tumors, as well as the possible effects on ovarian function.

DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors

February 12th 2024

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

Targeting NOTCH Pathway Signaling with Nirogacestat

February 5th 2024

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception

February 5th 2024

A panel of oncology experts provides insights into the management of desmoid tumors in women, focusing on special considerations for pregnancy and contraception.

The Role of Supportive Care Measures in Patients with Desmoid Tumors

January 29th 2024

Jonathan Trent, MD, PhD, discusses the role of approaches using low-dose and conventional chemotherapy, emphasizing key consideration factors for patient selection.

Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy

January 29th 2024

Mark Agulnik, MD, gives a summary of approaches to systemic therapy in the management of desmoid tumors, highlighting the diminishing role of chemotherapy and the shift towards targeted therapies.

Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors

January 22nd 2024

Chandrajit Raut, MD, explores the role of radiotherapy and other locoregional strategies in desmoid tumor management, highlighting the emerging role of cryoablation and HIFU.

The Evolving Role of Surgery in the Management of Desmoid Tumors

January 22nd 2024

Chandrajit Raut, MD, shares expert insights into the evolving role of surgical strategies for desmoid tumor management, emphasizing essential factors in patient selection.

Active Surveillance in Frontline Management of Desmoid Tumors

January 15th 2024

A panel of oncology experts examine the significance of employing active surveillance as a primary strategy in the treatment of desmoid tumors, providing expert insights into this approach.

Signs and Symptoms of Desmoid Tumors and Their Impact on Quality of Life

January 15th 2024

Mark Agulnik, MD, discusses signs and symptoms commonly presenting with desmoid tumors and their impact on quality of life for patients.

Expert Perspectives on the Pathogenesis and Diagnosis of Desmoid Tumors

December 20th 2023

Marilyn Bui, MD, PhD, explores the pathogenesis and diagnosis of desmoid tumors, emphasizing the significance of a multidisciplinary diagnostic approach.

An Overview of the Landscape Surrounding Desmoid Tumors

December 20th 2023

Chandrajit Raut, MD, provides an overview of the landscape surrounding desmoid tumors, highlighting associated epidemiology and common characteristics.

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

February 22nd 2018

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.